Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
New solvent-free micronization technology expanded at the Darmstadt site in Germany
If approved in the European Union, Fruquintinib will be the first novel targeted therapy for Metastatic Colorectal Cancer regardless of biomarker status in over a decade
Laurus Labs has reported total income of Rs. 1,458.20 crores during the period ended March 31, 2024
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Open a printable version of this pageEmail the URL of this page to a friend
Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of US$ 1,019 million in the US
Subscribe To Our Newsletter & Stay Updated
